Showing 4041-4050 of 5646 results for "".
- Keranova Announces Clinical Study Results for Robotic Laser Technologyhttps://modernod.com/news/keranova-announces-clinical-study-results-for-robotic-laser-technology/2481345/Keranova announced the finalization of the regulatory clinical studies of FemtoMatrix, its robotic laser technology. With the positive results, the company said it will now apply for CE marking for this new class of surgical equipment in cataract surgery. According to Ker
- Staar Surgical Announces Partnership with Actress Peyton Listhttps://modernod.com/news/staar-surgical-announces-partnership-with-actress-peyton-list/2481344/Staar Surgical announced a partnership with actress and beauty entrepreneur, Peyton List, to promote the EVO Implantable Collamer Lenses (EVO), which recevied FDA approval in 2022 for the correction of myopia with or without astigmatism. In December 2022, Ms. Li
- Neurotech Pharmaceuticals Appoints Scott Hunter as Chief Commercial Officerhttps://modernod.com/news/neurotech-pharmaceuticals-appoints-scott-hunter-as-chief-commercial-officer/2481341/Neurotech Pharmaceuticals announced the expansion of its executive team with the appointment of Scott Hunter as Chief Commercial Officer bringing two decades of eye care experience across both rare disease and specialty markets. “Scott’s appointment as the company&rsquo
- Acelyrin Acquires ValenzaBio, Maker of Treatment Candidate for Thyroid Eye Diseasehttps://modernod.com/news/acelyrin-acquires-valenzabio-maker-of-treatment-candidate-for-thyroid-eye-disease/2481339/Acelyrin announced the acquisition of ValenzaBio, a privately held company developing therapies for autoimmune and inflammatory diseases, in an all-stock transaction. Financial terms of the deal were not disclosed. The acquisition of ValenzaBi
- Ocuphire Pharma Announces First Patient Enrolled in VEGA-2 Pivotal Phase 3 Trial of Nyxol in Presbyopiahttps://modernod.com/news/ocuphire-pharma-announces-first-patient-enrolled-in-vega-2-pivotal-phase-3-trial-of-nyxol-in-presbyopia/2481333/Ocuphire Pharma announced the initiation of the VEGA-2 phase 3 pivotal trial with the first patient enrolled in late December. VEGA-2 is evaluating the efficacy and safety for two labels: Nyxol alone and Nyxol with adjunctive low-dose pilocarpine (LDP) therapy for presbyopia.
- EyeCare Partners Expands Footprint in Oklahoma with Retinal Associates of Oklahomahttps://modernod.com/news/eyecare-partners-expands-footprint-in-oklahoma-with-retinal-associates-of-oklahoma/2481328/EyeCare Partners (ECP) announced that it has expanded its presence in Oklahoma through a partnership with Retinal Associates of Oklahoma (RAO). Terms of the deal were not disclosed. The ECP network welcomes Darin R. Haivala, MD, and Rob
- Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences, Establishing New Eye Care Divisionhttps://modernod.com/news/viatris-closes-acquisitions-of-oyster-point-pharma-and-famy-life-sciences-establishing-new-viatris-eye-care-division-1/2481326/Viatris announced that it has closed its acquisitions of Oyster Point Pharma and Famy Life Sciences to establish a new Viatris Eye Care Division. The transaction was first announced on November 7. Former Oyster Point Pharma CEO, Jeffrey Nau, PhD, MMS, will lead the new di
- EyePoint Pharmaceuticals Promotes Jay S. Duker, MD, to President and Chief Operating Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-promotes-jay-s-duker-md-to-president-and-chief-operating-officer/2481320/EyePoint Pharmaceuticals announced that Jay S. Duker, MD, who has served as the company’s Chief Operating Officer (COO) since November 2021, has been promoted to the additional role of President. In addition to continuing to oversee his duties as COO, in his expanded role, Dr. Duker wi
- Iveric Bio Announces the Addition of Pravin U. Dugel, MD, to its Board of Directorshttps://modernod.com/news/iveric-bio-announces-the-addition-of-pravin-u-dugel-md-to-its-board-of-directors/2481317/Iveric bio announced the election of Pravin U. Dugel, MD, President of Iveric Bio, to its Board of Directors, effective as of January 1, 2023. Dr. Dugel has been instrumental in helping to shape the company’s business strategy and in overseeing the development and regulatory submission
- Bausch + Lomb and Glaucoma Research Foundation Announce Launch of "Screen, Protect, Cure" Campaignhttps://modernod.com/news/bausch-lomb-and-glaucoma-research-foundation-announce-launch-of-screen-protect-cure-campaign/2481316/Bausch + Lomb and Glaucoma Research Foundation (GRF) announced the US launch of "Screen, Protect, Cure," a campaign designed to provide educational resources and raise awareness of glaucoma during Glaucoma Awareness Month. “We are proud to collaborate with Glau